{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-008037","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.243036+00:00","generated_at":"2026-06-27T03:01:04.232629+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"REGENXBIO reports Q4 net income $294M on AbbVie deal; cash $849M into 2025","bullets":["Q4 2021 net income $294M ($6.87 basic EPS) vs net loss $46.2M in Q4 2020; revenue $398.7M (incl $370M AbbVie upfront).","Cash, equivalents & marketable securities $849.3M at Dec 31, 2021; runway into 2025.","Closed eye care collaboration with AbbVie: $370M upfront + up to $1.38B milestones; two pivotal trials (ATMOSPHERE, ASCENT) for wet AMD.","RGX-202: FDA cleared IND, granted Rare Pediatric Disease & Orphan Drug designations; Phase I/II AFFINITY DUCHENNE trial to start H1 2022.","RGX-314 suprachoroidal: Phase II AAVIATE (wet AMD) & ALTITUDE (DR) show reduced treatment burden; enrollment in higher-dose cohorts ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-008037","json":"https://secwatch.observer/filing/0001564590-22-008037.json","markdown":"https://secwatch.observer/filing/0001564590-22-008037.md","text":"https://secwatch.observer/filing/0001564590-22-008037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/0001564590-22-008037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/rgnx-8k_20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:01:04.232629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}